What the tirzepatide trials found — and what it means for you

You've read a headline figure, here's what the trial actually tested

Most people arrive at this topic because they've seen a number: 20%, sometimes more, sometimes less. The figure is real, but understanding what surrounds it matters. SURMOUNT-1, the pivotal trial for tirzepatide in weight management, enrolled 2,539 adults who had a BMI of 40 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Participants did not have type 2 diabetes.

Over 72 weeks, those on the 15mg dose saw an average weight reduction of around 20–21% of their starting body weight. The 10mg dose produced roughly 19% on average. Every dose outperformed placebo by a wide margin. These weren't passive participants either, everyone in the trial followed a reduced-calorie diet and increased their activity levels, which is exactly how tirzepatide is licensed for use in the UK.

One thing worth knowing before reading any trial summary: average figures include people who responded strongly and people who responded modestly. Your own result, should you be found suitable for treatment, would be shaped by factors a prescriber discusses with you. For a fuller look at what the UK trials picture looks like, the tirzepatide trial UK page covers the local regulatory context in detail.

Why tirzepatide's dual mechanism caught researchers' attention

A question our prescribers hear most weeks is why tirzepatide produced larger losses than older GLP-1 medicines in the same trial settings. The short answer is the second receptor. Tirzepatide is a dual GIP and GLP-1 receptor agonist, it activates two separate gut-hormone pathways involved in appetite regulation, insulin response and gastric emptying. GLP-1 agonists like semaglutide work on one pathway. Whether that second mechanism is the primary driver of the larger weight effect is still being studied, but the clinical outcome difference is well established in the trial record.

SURMOUNT-5 is the clearest illustration of this. In that open-label, 72-week head-to-head trial involving 751 adults with obesity and without diabetes, tirzepatide produced a statistically greater average weight reduction than semaglutide 2.4mg. NICE's appraisal of tirzepatide (TA1026) reviewed this evidence carefully before recommending it for NHS use. The committee noted that indirect comparisons favoured tirzepatide, and SURMOUNT-5 strengthened that picture with direct data.

You can read more about the specific head-to-head findings on the SURMOUNT trials overview page, which unpacks each study in the programme. For how the broader UK trial landscape shaped NHS access, the Mounjaro trials and UK approval page covers the regulatory journey from evidence to licence.

What the trial results mean for eligibility, and what they don't guarantee

Trial populations define who the evidence applies to most directly. SURMOUNT-1's entry criteria (BMI 30 or above, or 27 or above with a weight-related condition) broadly match the UK private prescribing licence. NICE's NHS recommendation (TA1026) sets a higher bar: a BMI of 35 or above plus at least one qualifying comorbidity, with lower thresholds for certain ethnic backgrounds under UK guidance.

A meaningful point often buried in trial reporting: participants who lost less than 5% of their body weight after six months on the highest tolerated dose were assessed for whether to continue. NICE reflects this in its recommendations. It reinforces that the trials were designed to identify who benefits most, not to suggest the medicine works identically for everyone.

None of this translates to a guaranteed outcome for any individual. Trial averages describe a population; a prescriber's job is to assess whether you, specifically, are likely to benefit and whether treatment is safe given your medical history. The Mounjaro weight-loss trials page explores how these results are applied in clinical practice, and the tirzepatide CKD trial page covers emerging evidence in specific comorbidity settings. You can also read about the medicine itself on the tirzepatide overview page and the Mounjaro page.

If you're trying to work out whether the trial evidence applies to your situation, that's exactly the conversation a prescriber is there to have. You can also browse our weight-loss treatment options or compare considerations on the Mounjaro price comparison page if cost is part of your thinking. When you're ready, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, never automated software.